Autolus Therapeutics (AUTL) said Friday that its obecabtagene autoleucel therapy has been recommended for European Commission approval by the European Medicines Agency's Committee for Medicinal Products for Human Use for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
The commission is expected to make a decision on the conditional marketing authorization application for the therapy within two months, with the decision applying to all EU member states, Iceland, Norway, and Liechtenstein, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.